A CIBMTR Prognostic Model for Progression-Free Survival (PFS) After Autologous Hematopoietic Cell Transplantation (AHCT) for Relapsed or Refractory Hodgkin Lymphoma (HL)

被引：0
|
作者：
Hahn, Theresa [1 ]
McCarthy, Philip L., Jr. [1 ]
Carreras, Jeanette [2 ]
Zhang, Mei-Jie
Lazarus, Hillard M. [3 ]
Laport, Ginna G. [4 ]
Montoto, Silvia [5 ]
Maloney, David G. [6 ]
Hari, Parameswaran [2 ]
机构：
[1] Roswell Pk Canc Inst, Med BMT Program, Buffalo, NY 14263 USA
[2] Med Coll Wisconsin, CIBMTR, Milwaukee, WI 53226 USA
[3] Univ Hosp Case Med Ctr, Cleveland, OH USA
[4] Stanford Univ, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA
[5] QMUL, Barts Canc Inst, Ctr Haematol Oncol, London, England
[6] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：232 / 233
页数：2
相关论文
共 50 条
  • [41] Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma
    S Murali
    E Winton
    E K Waller
    L T Heffner
    S Lonial
    C Flowers
    J Kaufman
    M Arellano
    M J Lechowicz
    K P Mann
    H J Khoury
    A A Langston
    Bone Marrow Transplantation, 2008, 42 : 529 - 534
  • [42] Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma
    Murali, S.
    Winton, E.
    Waller, E. K.
    Heffner, L. T.
    Lonial, S.
    Flowers, C.
    Kaufman, J.
    Arellano, M.
    Lechowicz, M. J.
    Mann, K. P.
    Khoury, H. J.
    Langston, A. A.
    BONE MARROW TRANSPLANTATION, 2008, 42 (08) : 529 - 534
  • [43] Early lymphocyte recovery predicts for progression-free survival (PFS) in Hodgkin lymphoma (HL) patients following autologous stem cell transplant (ASCT) using the same ablative regimen.
    Oliveira, MR
    Hyashi, M
    Magalhaes-Silverma, M
    Ritchie, J
    Hohl, R
    Lee, CK
    Schluetter, A
    Gingrich, RD
    BLOOD, 2002, 100 (11) : 648A - 648A
  • [44] Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma
    U Popat
    C Hosing
    R M Saliba
    P Anderlini
    K van Besien
    D Przepiorka
    I F Khouri
    J Gajewski
    D Claxton
    S Giralt
    M Rodriguez
    J Romaguera
    F Hagemeister
    C Ha
    J Cox
    F Cabanillas
    B S Andersson
    R E Champlin
    Bone Marrow Transplantation, 2004, 33 : 1015 - 1023
  • [45] Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma
    Popat, U
    Hosing, C
    Saliba, RM
    Anderlini, P
    van Besien, K
    Przepiorka, D
    Khouri, IF
    Gajewski, J
    Claxton, D
    Giralt, S
    Rodriguez, M
    Romaguera, J
    Hagemeister, F
    Ha, C
    Cox, J
    Cabanillas, F
    Andersson, BS
    Champlin, R
    BONE MARROW TRANSPLANTATION, 2004, 33 (10) : 1015 - 1023
  • [46] Long-term outcomes of survivors of autologous hematopoietic cell transplantation for refractory/relapsed Hodgkin's lymphoma
    Minn, Y.
    Halpern, J.
    Johnston, L.
    Horning, S.
    Goodman, K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S500 - S501
  • [47] Long-term outcome of survivors of autologous hematopoietic-cell transplantation for refractory and relapsed Hodgkin lymphoma
    Goodman, K. A.
    Riedel, E.
    Serrano, V.
    Gonzales, A. M.
    Gulati, S.
    Moskowitz, C.
    Yahalom, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 48 - 49
  • [48] Brentuximab Vedotin Is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma
    Chen, Robert
    Palmer, Joycelynne M.
    Tsai, Ni-Chun
    Thomas, Sandra H.
    Siddiqi, Tanya
    Popplewell, Leslie
    Faro, Len
    Nademanee, Auayporn
    Forman, Stephen J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (11) : 1864 - 1868
  • [49] Brentuximab vedotin for relapse or progression therapy after allogeneic hematopoietic stem cell transplantation in relapsed / refractory classic Hodgkin lymphoma
    Mikhailova, N.
    Popova, M.
    Kondakova, E.
    Ivanova, M.
    Borzenkova, E.
    Alaynskiy, A.
    Bondarenko, S.
    Afanasyev, B.
    Babenko, E.
    BONE MARROW TRANSPLANTATION, 2016, 51 : S503 - S503
  • [50] THE PROGNOSTIC SIGNIFICANCE OF PET SCAN BEFORE AND AFTER HIGH-DOSE THERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA (HL) PATIENTS
    Angelopoulou, M.
    Moschogiannis, M.
    Rondogianni, P.
    Pappis, V.
    Tsirkinidis, P.
    Tsopra, O.
    Galani, Z.
    Sachanas, S.
    Yiakoumis, X.
    Masouridi, S.
    Boutsikas, G.
    Kalpadakis, C.
    Dimitriadou, E.
    Dimopoulou, M.
    Telonis, V.
    Flevari, P.
    Gainarou, G.
    Ntalagiorgos, T.
    Exarchos, D.
    Datseris, I.
    Gouliamos, A.
    Kyrtsonis, M. C.
    Panayiotidis, P.
    Pangalis, G.
    Meletis, I.
    Vassilakopoulos, T.
    HAEMATOLOGICA, 2012, 97 : 178 - 179
12345